Seribantumab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | HER3 |
Clinical data | |
Other names | MM-121 |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6340H9810N1690O1986S52 |
Molar mass | 143151.18 g·mol−1 |
Seribantumab (INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2]
This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.
References[]
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
This monoclonal antibody–related article is a stub. You can help Wikipedia by . |
- v
- t
Monoclonal antibodies for tumors | |
---|---|
Tumor | |
|
Growth factor receptor modulators | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Angiopoietin |
| ||||||||||
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF | |||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) | |||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
Retrieved from ""
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibody stubs
- Monoclonal antibodies
- Experimental cancer drugs
Hidden categories:
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles